pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,707 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5005Rare Disease852Cardiology802Hematology772Immunology736Psychiatry & CNS582Pulmonology
  • Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending
    Novartis CEO Vas Narasimhan said the Swiss company is “very disappointed” by Germany’s plan to shave off more than €60 billion in healthcare costs that would affect pharma sales. Germany wants to s…
    Endpoints · 3mo ago↗ source
  • Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
    Obesity patients taking the weight loss injection being developed by Boehringer Ingelheim lost nearly 17% of their weight after about a year and a half, the company said Tuesday. The results are mo…
    Endpoints · 3mo ago↗ source
  • Opinion: It’s time to seize the rare bipartisan opening to address microplastics
    “This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write Tim Ryan and Justin Zorn.
← prev
page 66 of 69
next →
23
fda press21
fda medwatch18
571
Vaccines517
Endocrinology & Metabolism293
Ophthalmology264
Infectious Disease253
Nephrology239
STAT · 3mo ago↗ source
  • Opinion: Why do discussions about ‘brain health’ ignore mental illness?
    “Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K. Manji, Eric J. Nestler, and Patrick J. Kennedy.
    STAT · 3mo ago↗ source
  • STAT+: A giant question looms over GOP’s new Medicaid work requirements
    Coverage losses tied to Medicaid work requirements may not be tracked in every states.
    STAT · 3mo ago↗ source
  • STAT+: Google clinical director says AI can be a ‘bridge’ for people having a mental health crisis
    Google's clinical director Megan Bell Jones on how the company is addressing concerns over mental health impacts of its AI products.
    STAT · 3mo ago↗ source
  • New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies project
    Policy that recommends offering hep B vaccine at birth only to babies perceived to be at risk will lead to increased numbers of infected infants, new studies project.
    STAT · 3mo ago↗ source
  • Supreme Court grapples with multibillion-dollar wave of lawsuits over Roundup cancer claims
    The Supreme Court seemed divided Monday over whether to block thousands of lawsuits alleging the maker of the weedkiller Roundup failed to warn people it could cause cancer.
    STAT · 3mo ago↗ source
  • STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
    The drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer exceeded its expectations.
    STAT · 3mo ago↗ source
  • Erasca reports RAS cancer drug data after legal threat from Revolution
    After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown b…
    Endpoints · 3mo ago↗ source
  • STAT+: Dems say RFK Jr. has a pattern of failing to answer their questions
    Kennedy broke his pledge to share a controversial contract, highlighting Democrats' frustrations with the health secretary.
    STAT · 3mo ago↗ source
  • Revolution Medicines threatens to sue Erasca over patent, efficacy claims
    Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, Erasca said it had received a legal threat from Revolution Medicines' lawyers ove…
    Endpoints · 3mo ago↗ source
  • Trump administration warns against using federal dollars on fentanyl test strips
    The Trump administration underlines a “clear shift away from harm reduction and practices” that it says facilitates illegal drug use.
    STAT · 3mo ago↗ source
  • Utah doctors demand suspension of Doctronic AI program
    Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications. The startup, Doctronic, struck an ag…
    Endpoints · 3mo ago↗ source
  • Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next
    Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous…
    Endpoints · 3mo ago↗ source
  • Thermo Fisher sells microbiology biz; Ligand to buy XOMA
    Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of its specialt…
    Endpoints · 3mo ago↗ source
  • STAT+: An insider reveals the real goals of prior authorization
    Years ago, Archelle Georgiou helped squash prior auths at one of America's biggest health insurers.
    STAT · 3mo ago↗ source
  • Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
    Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…
    Endpoints · 3mo ago↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
    Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
    STAT · 3mo ago↗ source
  • What’s the true risk for eating disorders with GLP-1s?
    The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning Rounds
    STAT · 3mo ago↗ source
  • Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
    Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
    Endpoints · 3mo ago↗ source
  • Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial
    A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…
    Endpoints · 3mo ago↗ source
  • Intellia's in vivo CRISPR therapy first to succeed in Phase 3
    An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…
    Endpoints · 3mo ago↗ source
  • STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
    With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
    STAT · 3mo ago↗ source